nodes	percent_of_prediction	percent_of_DWPC	metapath
Degarelix—prostate cancer—urinary bladder cancer	0.894	1	CtDrD
Degarelix—Musculoskeletal discomfort—Cisplatin—urinary bladder cancer	0.000129	0.00122	CcSEcCtD
Degarelix—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.000129	0.00122	CcSEcCtD
Degarelix—Dysuria—Methotrexate—urinary bladder cancer	0.000128	0.00121	CcSEcCtD
Degarelix—Pruritus—Thiotepa—urinary bladder cancer	0.000128	0.00121	CcSEcCtD
Degarelix—Pain—Fluorouracil—urinary bladder cancer	0.000128	0.00121	CcSEcCtD
Degarelix—Dyspnoea—Cisplatin—urinary bladder cancer	0.000126	0.00119	CcSEcCtD
Degarelix—Skin disorder—Etoposide—urinary bladder cancer	0.000126	0.00119	CcSEcCtD
Degarelix—Erectile dysfunction—Methotrexate—urinary bladder cancer	0.000126	0.00119	CcSEcCtD
Degarelix—Hyperhidrosis—Etoposide—urinary bladder cancer	0.000125	0.00118	CcSEcCtD
Degarelix—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.000125	0.00118	CcSEcCtD
Degarelix—Breast disorder—Doxorubicin—urinary bladder cancer	0.000124	0.00117	CcSEcCtD
Degarelix—Diarrhoea—Thiotepa—urinary bladder cancer	0.000124	0.00117	CcSEcCtD
Degarelix—Decreased appetite—Cisplatin—urinary bladder cancer	0.000123	0.00116	CcSEcCtD
Degarelix—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.000123	0.00116	CcSEcCtD
Degarelix—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000122	0.00115	CcSEcCtD
Degarelix—Depression—Methotrexate—urinary bladder cancer	0.000121	0.00115	CcSEcCtD
Degarelix—Hypotension—Etoposide—urinary bladder cancer	0.000121	0.00115	CcSEcCtD
Degarelix—Pain—Cisplatin—urinary bladder cancer	0.000121	0.00114	CcSEcCtD
Degarelix—Muscular weakness—Doxorubicin—urinary bladder cancer	0.000121	0.00114	CcSEcCtD
Degarelix—Body temperature increased—Gemcitabine—urinary bladder cancer	0.00012	0.00113	CcSEcCtD
Degarelix—Renal failure—Methotrexate—urinary bladder cancer	0.00012	0.00113	CcSEcCtD
Degarelix—Dysuria—Epirubicin—urinary bladder cancer	0.00012	0.00113	CcSEcCtD
Degarelix—Dizziness—Thiotepa—urinary bladder cancer	0.000119	0.00113	CcSEcCtD
Degarelix—Urticaria—Fluorouracil—urinary bladder cancer	0.000119	0.00112	CcSEcCtD
Degarelix—Pollakiuria—Epirubicin—urinary bladder cancer	0.000118	0.00112	CcSEcCtD
Degarelix—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000118	0.00112	CcSEcCtD
Degarelix—Feeling abnormal—Cisplatin—urinary bladder cancer	0.000117	0.0011	CcSEcCtD
Degarelix—Weight increased—Epirubicin—urinary bladder cancer	0.000116	0.0011	CcSEcCtD
Degarelix—Weight decreased—Epirubicin—urinary bladder cancer	0.000116	0.00109	CcSEcCtD
Degarelix—Dyspnoea—Etoposide—urinary bladder cancer	0.000116	0.00109	CcSEcCtD
Degarelix—Hyperglycaemia—Epirubicin—urinary bladder cancer	0.000115	0.00109	CcSEcCtD
Degarelix—Hepatobiliary disease—Methotrexate—urinary bladder cancer	0.000115	0.00109	CcSEcCtD
Degarelix—Vomiting—Thiotepa—urinary bladder cancer	0.000115	0.00108	CcSEcCtD
Degarelix—Rash—Thiotepa—urinary bladder cancer	0.000114	0.00108	CcSEcCtD
Degarelix—Dermatitis—Thiotepa—urinary bladder cancer	0.000114	0.00107	CcSEcCtD
Degarelix—Headache—Thiotepa—urinary bladder cancer	0.000113	0.00107	CcSEcCtD
Degarelix—Decreased appetite—Etoposide—urinary bladder cancer	0.000113	0.00107	CcSEcCtD
Degarelix—Renal failure—Epirubicin—urinary bladder cancer	0.000112	0.00106	CcSEcCtD
Degarelix—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000112	0.00106	CcSEcCtD
Degarelix—Body temperature increased—Cisplatin—urinary bladder cancer	0.000112	0.00106	CcSEcCtD
Degarelix—Fatigue—Etoposide—urinary bladder cancer	0.000112	0.00106	CcSEcCtD
Degarelix—Pain—Etoposide—urinary bladder cancer	0.000111	0.00105	CcSEcCtD
Degarelix—Constipation—Etoposide—urinary bladder cancer	0.000111	0.00105	CcSEcCtD
Degarelix—Urinary tract infection—Epirubicin—urinary bladder cancer	0.000111	0.00105	CcSEcCtD
Degarelix—Dysuria—Doxorubicin—urinary bladder cancer	0.000111	0.00105	CcSEcCtD
Degarelix—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.00011	0.00104	CcSEcCtD
Degarelix—Pollakiuria—Doxorubicin—urinary bladder cancer	0.000109	0.00103	CcSEcCtD
Degarelix—Asthenia—Gemcitabine—urinary bladder cancer	0.000109	0.00103	CcSEcCtD
Degarelix—Urinary tract disorder—Methotrexate—urinary bladder cancer	0.000108	0.00102	CcSEcCtD
Degarelix—Hepatobiliary disease—Epirubicin—urinary bladder cancer	0.000108	0.00102	CcSEcCtD
Degarelix—Weight increased—Doxorubicin—urinary bladder cancer	0.000108	0.00102	CcSEcCtD
Degarelix—Pruritus—Gemcitabine—urinary bladder cancer	0.000107	0.00102	CcSEcCtD
Degarelix—Nausea—Thiotepa—urinary bladder cancer	0.000107	0.00101	CcSEcCtD
Degarelix—Urethral disorder—Methotrexate—urinary bladder cancer	0.000107	0.00101	CcSEcCtD
Degarelix—Weight decreased—Doxorubicin—urinary bladder cancer	0.000107	0.00101	CcSEcCtD
Degarelix—Feeling abnormal—Etoposide—urinary bladder cancer	0.000107	0.00101	CcSEcCtD
Degarelix—Hyperglycaemia—Doxorubicin—urinary bladder cancer	0.000107	0.00101	CcSEcCtD
Degarelix—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000106	0.001	CcSEcCtD
Degarelix—Pruritus—Fluorouracil—urinary bladder cancer	0.000106	0.000998	CcSEcCtD
Degarelix—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000104	0.000986	CcSEcCtD
Degarelix—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000104	0.000982	CcSEcCtD
Degarelix—Renal failure—Doxorubicin—urinary bladder cancer	0.000104	0.00098	CcSEcCtD
Degarelix—Urticaria—Etoposide—urinary bladder cancer	0.000103	0.000974	CcSEcCtD
Degarelix—Abdominal pain—Etoposide—urinary bladder cancer	0.000103	0.000969	CcSEcCtD
Degarelix—Body temperature increased—Etoposide—urinary bladder cancer	0.000103	0.000969	CcSEcCtD
Degarelix—Urinary tract infection—Doxorubicin—urinary bladder cancer	0.000103	0.000969	CcSEcCtD
Degarelix—Eye disorder—Methotrexate—urinary bladder cancer	0.000102	0.000966	CcSEcCtD
Degarelix—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000102	0.000966	CcSEcCtD
Degarelix—Hypoaesthesia—Epirubicin—urinary bladder cancer	0.000102	0.000962	CcSEcCtD
Degarelix—Asthenia—Cisplatin—urinary bladder cancer	0.000102	0.00096	CcSEcCtD
Degarelix—Cardiac disorder—Methotrexate—urinary bladder cancer	0.000101	0.000959	CcSEcCtD
Degarelix—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.000101	0.000955	CcSEcCtD
Degarelix—Oedema peripheral—Epirubicin—urinary bladder cancer	0.000101	0.000953	CcSEcCtD
Degarelix—Urethral disorder—Epirubicin—urinary bladder cancer	0.0001	0.000948	CcSEcCtD
Degarelix—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	9.97e-05	0.000943	CcSEcCtD
Degarelix—Angiopathy—Methotrexate—urinary bladder cancer	9.92e-05	0.000937	CcSEcCtD
Degarelix—Immune system disorder—Methotrexate—urinary bladder cancer	9.88e-05	0.000933	CcSEcCtD
Degarelix—Dizziness—Fluorouracil—urinary bladder cancer	9.87e-05	0.000933	CcSEcCtD
Degarelix—Mediastinal disorder—Methotrexate—urinary bladder cancer	9.85e-05	0.000931	CcSEcCtD
Degarelix—Chills—Methotrexate—urinary bladder cancer	9.81e-05	0.000927	CcSEcCtD
Degarelix—Diarrhoea—Cisplatin—urinary bladder cancer	9.69e-05	0.000915	CcSEcCtD
Degarelix—Alopecia—Methotrexate—urinary bladder cancer	9.66e-05	0.000913	CcSEcCtD
Degarelix—Vomiting—Gemcitabine—urinary bladder cancer	9.66e-05	0.000913	CcSEcCtD
Degarelix—Mental disorder—Methotrexate—urinary bladder cancer	9.58e-05	0.000905	CcSEcCtD
Degarelix—Rash—Gemcitabine—urinary bladder cancer	9.58e-05	0.000905	CcSEcCtD
Degarelix—Dermatitis—Gemcitabine—urinary bladder cancer	9.57e-05	0.000904	CcSEcCtD
Degarelix—Eye disorder—Epirubicin—urinary bladder cancer	9.56e-05	0.000904	CcSEcCtD
Degarelix—Hypersensitivity—Etoposide—urinary bladder cancer	9.55e-05	0.000903	CcSEcCtD
Degarelix—Erythema—Methotrexate—urinary bladder cancer	9.52e-05	0.000899	CcSEcCtD
Degarelix—Malnutrition—Methotrexate—urinary bladder cancer	9.52e-05	0.000899	CcSEcCtD
Degarelix—Headache—Gemcitabine—urinary bladder cancer	9.51e-05	0.000899	CcSEcCtD
Degarelix—Cardiac disorder—Epirubicin—urinary bladder cancer	9.5e-05	0.000897	CcSEcCtD
Degarelix—Vomiting—Fluorouracil—urinary bladder cancer	9.49e-05	0.000897	CcSEcCtD
Degarelix—Hypoaesthesia—Doxorubicin—urinary bladder cancer	9.42e-05	0.00089	CcSEcCtD
Degarelix—Rash—Fluorouracil—urinary bladder cancer	9.41e-05	0.00089	CcSEcCtD
Degarelix—Dermatitis—Fluorouracil—urinary bladder cancer	9.41e-05	0.000889	CcSEcCtD
Degarelix—Headache—Fluorouracil—urinary bladder cancer	9.35e-05	0.000884	CcSEcCtD
Degarelix—Urinary tract disorder—Doxorubicin—urinary bladder cancer	9.35e-05	0.000884	CcSEcCtD
Degarelix—Oedema peripheral—Doxorubicin—urinary bladder cancer	9.33e-05	0.000881	CcSEcCtD
Degarelix—Asthenia—Etoposide—urinary bladder cancer	9.3e-05	0.000879	CcSEcCtD
Degarelix—Angiopathy—Epirubicin—urinary bladder cancer	9.28e-05	0.000877	CcSEcCtD
Degarelix—Urethral disorder—Doxorubicin—urinary bladder cancer	9.28e-05	0.000877	CcSEcCtD
Degarelix—Immune system disorder—Epirubicin—urinary bladder cancer	9.24e-05	0.000873	CcSEcCtD
Degarelix—Mediastinal disorder—Epirubicin—urinary bladder cancer	9.22e-05	0.000871	CcSEcCtD
Degarelix—Back pain—Methotrexate—urinary bladder cancer	9.21e-05	0.00087	CcSEcCtD
Degarelix—Chills—Epirubicin—urinary bladder cancer	9.18e-05	0.000868	CcSEcCtD
Degarelix—Pruritus—Etoposide—urinary bladder cancer	9.17e-05	0.000867	CcSEcCtD
Degarelix—Arrhythmia—Epirubicin—urinary bladder cancer	9.14e-05	0.000864	CcSEcCtD
Degarelix—Alopecia—Epirubicin—urinary bladder cancer	9.04e-05	0.000854	CcSEcCtD
Degarelix—Nausea—Gemcitabine—urinary bladder cancer	9.02e-05	0.000853	CcSEcCtD
Degarelix—Vomiting—Cisplatin—urinary bladder cancer	9e-05	0.000851	CcSEcCtD
Degarelix—Vision blurred—Methotrexate—urinary bladder cancer	8.97e-05	0.000848	CcSEcCtD
Degarelix—Mental disorder—Epirubicin—urinary bladder cancer	8.96e-05	0.000847	CcSEcCtD
Degarelix—Rash—Cisplatin—urinary bladder cancer	8.93e-05	0.000844	CcSEcCtD
Degarelix—Dermatitis—Cisplatin—urinary bladder cancer	8.92e-05	0.000843	CcSEcCtD
Degarelix—Erythema—Epirubicin—urinary bladder cancer	8.91e-05	0.000842	CcSEcCtD
Degarelix—Malnutrition—Epirubicin—urinary bladder cancer	8.91e-05	0.000842	CcSEcCtD
Degarelix—Diarrhoea—Etoposide—urinary bladder cancer	8.87e-05	0.000839	CcSEcCtD
Degarelix—Nausea—Fluorouracil—urinary bladder cancer	8.87e-05	0.000838	CcSEcCtD
Degarelix—Eye disorder—Doxorubicin—urinary bladder cancer	8.85e-05	0.000836	CcSEcCtD
Degarelix—Ill-defined disorder—Methotrexate—urinary bladder cancer	8.83e-05	0.000835	CcSEcCtD
Degarelix—Anaemia—Methotrexate—urinary bladder cancer	8.8e-05	0.000831	CcSEcCtD
Degarelix—Cardiac disorder—Doxorubicin—urinary bladder cancer	8.79e-05	0.00083	CcSEcCtD
Degarelix—Back pain—Epirubicin—urinary bladder cancer	8.62e-05	0.000814	CcSEcCtD
Degarelix—Angiopathy—Doxorubicin—urinary bladder cancer	8.59e-05	0.000812	CcSEcCtD
Degarelix—Malaise—Methotrexate—urinary bladder cancer	8.58e-05	0.000811	CcSEcCtD
Degarelix—Dizziness—Etoposide—urinary bladder cancer	8.58e-05	0.00081	CcSEcCtD
Degarelix—Muscle spasms—Epirubicin—urinary bladder cancer	8.56e-05	0.000809	CcSEcCtD
Degarelix—Immune system disorder—Doxorubicin—urinary bladder cancer	8.55e-05	0.000808	CcSEcCtD
Degarelix—Mediastinal disorder—Doxorubicin—urinary bladder cancer	8.53e-05	0.000806	CcSEcCtD
Degarelix—Chills—Doxorubicin—urinary bladder cancer	8.49e-05	0.000803	CcSEcCtD
Degarelix—Arrhythmia—Doxorubicin—urinary bladder cancer	8.46e-05	0.000799	CcSEcCtD
Degarelix—Nausea—Cisplatin—urinary bladder cancer	8.41e-05	0.000795	CcSEcCtD
Degarelix—Vision blurred—Epirubicin—urinary bladder cancer	8.39e-05	0.000793	CcSEcCtD
Degarelix—Alopecia—Doxorubicin—urinary bladder cancer	8.37e-05	0.000791	CcSEcCtD
Degarelix—Mental disorder—Doxorubicin—urinary bladder cancer	8.29e-05	0.000784	CcSEcCtD
Degarelix—Ill-defined disorder—Epirubicin—urinary bladder cancer	8.26e-05	0.000781	CcSEcCtD
Degarelix—Vomiting—Etoposide—urinary bladder cancer	8.25e-05	0.000779	CcSEcCtD
Degarelix—Malnutrition—Doxorubicin—urinary bladder cancer	8.24e-05	0.000779	CcSEcCtD
Degarelix—Erythema—Doxorubicin—urinary bladder cancer	8.24e-05	0.000779	CcSEcCtD
Degarelix—Anaemia—Epirubicin—urinary bladder cancer	8.23e-05	0.000778	CcSEcCtD
Degarelix—Rash—Etoposide—urinary bladder cancer	8.18e-05	0.000773	CcSEcCtD
Degarelix—Dermatitis—Etoposide—urinary bladder cancer	8.17e-05	0.000772	CcSEcCtD
Degarelix—Headache—Etoposide—urinary bladder cancer	8.12e-05	0.000768	CcSEcCtD
Degarelix—Arthralgia—Methotrexate—urinary bladder cancer	8.1e-05	0.000766	CcSEcCtD
Degarelix—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	8.05e-05	0.000761	CcSEcCtD
Degarelix—Malaise—Epirubicin—urinary bladder cancer	8.03e-05	0.000759	CcSEcCtD
Degarelix—Discomfort—Methotrexate—urinary bladder cancer	8.01e-05	0.000757	CcSEcCtD
Degarelix—Back pain—Doxorubicin—urinary bladder cancer	7.97e-05	0.000753	CcSEcCtD
Degarelix—Muscle spasms—Doxorubicin—urinary bladder cancer	7.92e-05	0.000749	CcSEcCtD
Degarelix—Palpitations—Epirubicin—urinary bladder cancer	7.87e-05	0.000744	CcSEcCtD
Degarelix—Anaphylactic shock—Methotrexate—urinary bladder cancer	7.77e-05	0.000734	CcSEcCtD
Degarelix—Vision blurred—Doxorubicin—urinary bladder cancer	7.77e-05	0.000734	CcSEcCtD
Degarelix—Nausea—Etoposide—urinary bladder cancer	7.7e-05	0.000728	CcSEcCtD
Degarelix—Hypertension—Epirubicin—urinary bladder cancer	7.69e-05	0.000727	CcSEcCtD
Degarelix—Ill-defined disorder—Doxorubicin—urinary bladder cancer	7.65e-05	0.000723	CcSEcCtD
Degarelix—Nervous system disorder—Methotrexate—urinary bladder cancer	7.62e-05	0.00072	CcSEcCtD
Degarelix—Anaemia—Doxorubicin—urinary bladder cancer	7.62e-05	0.00072	CcSEcCtD
Degarelix—Arthralgia—Epirubicin—urinary bladder cancer	7.58e-05	0.000717	CcSEcCtD
Degarelix—Skin disorder—Methotrexate—urinary bladder cancer	7.54e-05	0.000713	CcSEcCtD
Degarelix—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	7.53e-05	0.000712	CcSEcCtD
Degarelix—Hyperhidrosis—Methotrexate—urinary bladder cancer	7.51e-05	0.00071	CcSEcCtD
Degarelix—Discomfort—Epirubicin—urinary bladder cancer	7.49e-05	0.000708	CcSEcCtD
Degarelix—Malaise—Doxorubicin—urinary bladder cancer	7.43e-05	0.000702	CcSEcCtD
Degarelix—Dry mouth—Epirubicin—urinary bladder cancer	7.42e-05	0.000701	CcSEcCtD
Degarelix—Palpitations—Doxorubicin—urinary bladder cancer	7.28e-05	0.000688	CcSEcCtD
Degarelix—Anaphylactic shock—Epirubicin—urinary bladder cancer	7.27e-05	0.000687	CcSEcCtD
Degarelix—Hypotension—Methotrexate—urinary bladder cancer	7.26e-05	0.000686	CcSEcCtD
Degarelix—Nervous system disorder—Epirubicin—urinary bladder cancer	7.13e-05	0.000674	CcSEcCtD
Degarelix—Hypertension—Doxorubicin—urinary bladder cancer	7.12e-05	0.000672	CcSEcCtD
Degarelix—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	7.08e-05	0.000669	CcSEcCtD
Degarelix—Skin disorder—Epirubicin—urinary bladder cancer	7.06e-05	0.000667	CcSEcCtD
Degarelix—Hyperhidrosis—Epirubicin—urinary bladder cancer	7.03e-05	0.000664	CcSEcCtD
Degarelix—Insomnia—Methotrexate—urinary bladder cancer	7.03e-05	0.000664	CcSEcCtD
Degarelix—Arthralgia—Doxorubicin—urinary bladder cancer	7.02e-05	0.000663	CcSEcCtD
Degarelix—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	6.97e-05	0.000659	CcSEcCtD
Degarelix—Discomfort—Doxorubicin—urinary bladder cancer	6.93e-05	0.000655	CcSEcCtD
Degarelix—Dyspnoea—Methotrexate—urinary bladder cancer	6.93e-05	0.000654	CcSEcCtD
Degarelix—Dry mouth—Doxorubicin—urinary bladder cancer	6.86e-05	0.000649	CcSEcCtD
Degarelix—Hypotension—Epirubicin—urinary bladder cancer	6.79e-05	0.000642	CcSEcCtD
Degarelix—Decreased appetite—Methotrexate—urinary bladder cancer	6.75e-05	0.000638	CcSEcCtD
Degarelix—Anaphylactic shock—Doxorubicin—urinary bladder cancer	6.73e-05	0.000636	CcSEcCtD
Degarelix—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	6.71e-05	0.000634	CcSEcCtD
Degarelix—Fatigue—Methotrexate—urinary bladder cancer	6.7e-05	0.000633	CcSEcCtD
Degarelix—Pain—Methotrexate—urinary bladder cancer	6.64e-05	0.000628	CcSEcCtD
Degarelix—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	6.62e-05	0.000626	CcSEcCtD
Degarelix—Nervous system disorder—Doxorubicin—urinary bladder cancer	6.6e-05	0.000623	CcSEcCtD
Degarelix—Insomnia—Epirubicin—urinary bladder cancer	6.57e-05	0.000621	CcSEcCtD
Degarelix—Skin disorder—Doxorubicin—urinary bladder cancer	6.53e-05	0.000617	CcSEcCtD
Degarelix—Hyperhidrosis—Doxorubicin—urinary bladder cancer	6.5e-05	0.000615	CcSEcCtD
Degarelix—Dyspnoea—Epirubicin—urinary bladder cancer	6.48e-05	0.000612	CcSEcCtD
Degarelix—Feeling abnormal—Methotrexate—urinary bladder cancer	6.4e-05	0.000605	CcSEcCtD
Degarelix—Gastrointestinal pain—Methotrexate—urinary bladder cancer	6.35e-05	0.0006	CcSEcCtD
Degarelix—Decreased appetite—Epirubicin—urinary bladder cancer	6.32e-05	0.000597	CcSEcCtD
Degarelix—Hypotension—Doxorubicin—urinary bladder cancer	6.28e-05	0.000594	CcSEcCtD
Degarelix—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	6.28e-05	0.000593	CcSEcCtD
Degarelix—Fatigue—Epirubicin—urinary bladder cancer	6.27e-05	0.000592	CcSEcCtD
Degarelix—Constipation—Epirubicin—urinary bladder cancer	6.22e-05	0.000587	CcSEcCtD
Degarelix—Pain—Epirubicin—urinary bladder cancer	6.22e-05	0.000587	CcSEcCtD
Degarelix—Urticaria—Methotrexate—urinary bladder cancer	6.17e-05	0.000583	CcSEcCtD
Degarelix—Body temperature increased—Methotrexate—urinary bladder cancer	6.14e-05	0.00058	CcSEcCtD
Degarelix—Abdominal pain—Methotrexate—urinary bladder cancer	6.14e-05	0.00058	CcSEcCtD
Degarelix—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	6.13e-05	0.000579	CcSEcCtD
Degarelix—Insomnia—Doxorubicin—urinary bladder cancer	6.08e-05	0.000575	CcSEcCtD
Degarelix—Dyspnoea—Doxorubicin—urinary bladder cancer	6e-05	0.000567	CcSEcCtD
Degarelix—Feeling abnormal—Epirubicin—urinary bladder cancer	5.99e-05	0.000566	CcSEcCtD
Degarelix—Gastrointestinal pain—Epirubicin—urinary bladder cancer	5.94e-05	0.000562	CcSEcCtD
Degarelix—Decreased appetite—Doxorubicin—urinary bladder cancer	5.85e-05	0.000553	CcSEcCtD
Degarelix—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	5.81e-05	0.000549	CcSEcCtD
Degarelix—Fatigue—Doxorubicin—urinary bladder cancer	5.8e-05	0.000548	CcSEcCtD
Degarelix—Urticaria—Epirubicin—urinary bladder cancer	5.77e-05	0.000546	CcSEcCtD
Degarelix—Pain—Doxorubicin—urinary bladder cancer	5.75e-05	0.000544	CcSEcCtD
Degarelix—Constipation—Doxorubicin—urinary bladder cancer	5.75e-05	0.000544	CcSEcCtD
Degarelix—Abdominal pain—Epirubicin—urinary bladder cancer	5.75e-05	0.000543	CcSEcCtD
Degarelix—Body temperature increased—Epirubicin—urinary bladder cancer	5.75e-05	0.000543	CcSEcCtD
Degarelix—Hypersensitivity—Methotrexate—urinary bladder cancer	5.72e-05	0.000541	CcSEcCtD
Degarelix—Asthenia—Methotrexate—urinary bladder cancer	5.57e-05	0.000527	CcSEcCtD
Degarelix—Feeling abnormal—Doxorubicin—urinary bladder cancer	5.54e-05	0.000524	CcSEcCtD
Degarelix—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	5.5e-05	0.00052	CcSEcCtD
Degarelix—Pruritus—Methotrexate—urinary bladder cancer	5.5e-05	0.000519	CcSEcCtD
Degarelix—Hypersensitivity—Epirubicin—urinary bladder cancer	5.36e-05	0.000506	CcSEcCtD
Degarelix—Urticaria—Doxorubicin—urinary bladder cancer	5.34e-05	0.000505	CcSEcCtD
Degarelix—Abdominal pain—Doxorubicin—urinary bladder cancer	5.32e-05	0.000503	CcSEcCtD
Degarelix—Body temperature increased—Doxorubicin—urinary bladder cancer	5.32e-05	0.000503	CcSEcCtD
Degarelix—Diarrhoea—Methotrexate—urinary bladder cancer	5.31e-05	0.000502	CcSEcCtD
Degarelix—Asthenia—Epirubicin—urinary bladder cancer	5.22e-05	0.000493	CcSEcCtD
Degarelix—Pruritus—Epirubicin—urinary bladder cancer	5.14e-05	0.000486	CcSEcCtD
Degarelix—Dizziness—Methotrexate—urinary bladder cancer	5.14e-05	0.000485	CcSEcCtD
Degarelix—Diarrhoea—Epirubicin—urinary bladder cancer	4.97e-05	0.00047	CcSEcCtD
Degarelix—Hypersensitivity—Doxorubicin—urinary bladder cancer	4.96e-05	0.000468	CcSEcCtD
Degarelix—Vomiting—Methotrexate—urinary bladder cancer	4.94e-05	0.000467	CcSEcCtD
Degarelix—Rash—Methotrexate—urinary bladder cancer	4.9e-05	0.000463	CcSEcCtD
Degarelix—Dermatitis—Methotrexate—urinary bladder cancer	4.89e-05	0.000462	CcSEcCtD
Degarelix—Headache—Methotrexate—urinary bladder cancer	4.87e-05	0.00046	CcSEcCtD
Degarelix—Asthenia—Doxorubicin—urinary bladder cancer	4.83e-05	0.000456	CcSEcCtD
Degarelix—Dizziness—Epirubicin—urinary bladder cancer	4.81e-05	0.000454	CcSEcCtD
Degarelix—Pruritus—Doxorubicin—urinary bladder cancer	4.76e-05	0.00045	CcSEcCtD
Degarelix—Vomiting—Epirubicin—urinary bladder cancer	4.62e-05	0.000437	CcSEcCtD
Degarelix—Nausea—Methotrexate—urinary bladder cancer	4.61e-05	0.000436	CcSEcCtD
Degarelix—Diarrhoea—Doxorubicin—urinary bladder cancer	4.6e-05	0.000435	CcSEcCtD
Degarelix—Rash—Epirubicin—urinary bladder cancer	4.58e-05	0.000433	CcSEcCtD
Degarelix—Dermatitis—Epirubicin—urinary bladder cancer	4.58e-05	0.000433	CcSEcCtD
Degarelix—Headache—Epirubicin—urinary bladder cancer	4.55e-05	0.00043	CcSEcCtD
Degarelix—Dizziness—Doxorubicin—urinary bladder cancer	4.45e-05	0.00042	CcSEcCtD
Degarelix—Nausea—Epirubicin—urinary bladder cancer	4.32e-05	0.000408	CcSEcCtD
Degarelix—Vomiting—Doxorubicin—urinary bladder cancer	4.28e-05	0.000404	CcSEcCtD
Degarelix—Rash—Doxorubicin—urinary bladder cancer	4.24e-05	0.000401	CcSEcCtD
Degarelix—Dermatitis—Doxorubicin—urinary bladder cancer	4.24e-05	0.0004	CcSEcCtD
Degarelix—Headache—Doxorubicin—urinary bladder cancer	4.21e-05	0.000398	CcSEcCtD
Degarelix—Nausea—Doxorubicin—urinary bladder cancer	4e-05	0.000378	CcSEcCtD
